Miguel-Teodoro T Hernandez Garcia

13PUBLICATIONS
65CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.

Juan José Lahuerta, Jesús San-Miguel, Ana Jiménez-Ubieto

|Oct 01, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Marta Lasa, Laura Notarfranchi, Cristina Agullo

|Jul 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

María-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero

|Apr 29, 2024
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

A Medina-Herrera, I Vazquez, I Cuenca

|Dec 04, 2023
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.

Camila Guerrero, Noemi Puig, María-Teresa Cedena

|Jul 28, 2023
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Laura Rosiñol, Albert Oriol, Rafael Ríos

Pageof 3

Frequent Collaborators

12 joint publications

Juan-Jose Lahuerta

12 joint publications

Jesus San-Miguel

11 joint publications

María-Victoria Mateos

11 joint publications

Albert Ortiol